Park Ha Biological Technology Co Ltd (BYAH) FinancialsBYAHPark Ha Biological Technology Co Ltd

Evaluating the bottom line, Park Ha Biological Technology Co Ltd maintains a gross margin of 96.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -76.53%, while the net margin is -73.01%. These profitability ratios, combined with a Return on Equity (ROE) of -113.04%, provide a clear picture of how effectively BYAH converts its operational activities into shareholder value.

In the context of the broader market, BYAH competes directly with industry leaders such as NHTC and DRMA. With a market capitalization of $8.53M, it holds a leading position in the sector. When comparing efficiency, BYAH's gross margin of 96.36% stands against NHTC's 75.25% and DRMA's N/A. Such benchmarking helps identify whether Park Ha Biological Technology Co Ltd is trading at a premium or discount relative to its financial performance.

The company's financial performance is concerning, with a forward P/E of 0 and a negative P/E ratio of -5.635546, indicating that it is not currently generating profits. Additionally, the price-to-sales ratio is high at 18.10441, suggesting that the stock may be overvalued relative to its sales.